Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.
about
Risk of cancer in diabetes: the effect of metforminInsulin in central nervous system: more than just a peripheral hormoneRole of insulin in the type 2 diabetes therapy: past, present and futureRisk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitusRisk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitusCombinations of insulin and oral hypoglycaemic agents for people with type 2 diabetes mellitus on insulin treatmentDietary advice for treatment of type 2 diabetes mellitus in adultsInsulin monotherapy versus combinations of insulin with oral hypoglycaemic agents in patients with type 2 diabetes mellitusAdvances in diabetes for the millennium: drug therapy of type 2 diabetesOne-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trialDiabetes surgery: a new approach to an old diseaseImpact of self monitoring of blood glucose in the management of patients with non-insulin treated diabetes: open parallel group randomised trialHealth and economic impact of combining metformin with nateglinide to achieve glycemic control: Comparison of the lifetime costs of complications in the U.KFamily history, diabetes, and other demographic and risk factors among participants of the National Health and Nutrition Examination Survey 1999-2002Safety, efficacy, and early clinical experience of insulin degludec in Japanese people with diabetes mellitus: A first-year report from JapanTreatment of prediabetesAntidiabetic treatment with gliptins: focus on cardiovascular effects and outcomesAddressing unmet medical needs in type 2 diabetes: a narrative review of drugs under developmentIntensification of insulin therapy in patients with type 2 diabetes mellitus: an algorithm for basal-bolus therapyType 2 diabetes: etiology and reversibilityType 2 diabetes can be prevented with early pharmacological interventionStrategies for Diabetes Management: Using Newer Oral Combination Therapies Early in the DiseaseAssessing the efficacy and safety of combined DPP-4 inhibitor and insulin treatment in patients with type 2 diabetes: a meta-analysisCompliance with clinical practice guidelines for type 2 diabetes in rural patients: treatment gaps and opportunities for improvementGUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patientsThe longitudinal association between depressive symptoms and initiation of insulin therapy in people with type 2 diabetes in primary careThe short-term cost-effectiveness of once-daily liraglutide versus once-weekly exenatide for the treatment of type 2 diabetes mellitus in the United StatesGenomic Characterization of Metformin Hepatic ResponseAdenosine kinase inhibition selectively promotes rodent and porcine islet β-cell replicationEarly progression of diabetic nephropathy correlates with methylglyoxal-derived advanced glycation end productsThe management of type 2 diabetic patients with hypoglycaemic agentsInvestigational anti-hyperglycemic agents: the future of type 2 diabetes therapy?Development and validation of the insulin treatment appraisal scale (ITAS) in patients with type 2 diabetes.Effect of the look AHEAD study intervention on medication use and related cost to treat cardiovascular disease risk factors in individuals with type 2 diabetes.Effects of beta-cell rest on beta-cell function: a review of clinical and preclinical dataNear-normoglycaemic remission in African-Americans with Type 2 diabetes mellitus is associated with recovery of beta cell function.Newer insights into the drug delivery approaches of α-glucosidase inhibitors.Combined use of basal insulin analog and acarbose reduces postprandial glucose in patients with uncontrolled type 2 diabetes.Comparison of thrice-daily lispro 50/50 vs thrice-daily lispro in combination with sulfonylurea as initial insulin therapy for type 2 diabetesEffects of intermittent fasting on health markers in those with type 2 diabetes: A pilot study.
P2860
Q21284807-AF04C8E3-AB39-45CF-B861-289218718E21Q21296648-5E7E6E5B-6D04-4980-9646-825B5B1A3429Q22241148-B70780D0-7905-48CC-8F79-0F9029BB521FQ24235718-7BA53AE7-F581-4C86-ADF9-0F657D4B47CAQ24240522-0EA27889-8159-4013-90FD-E7822342DD5DQ24243407-6183501C-0573-4FB4-8AF4-5B4C2E44C4C0Q24243869-DB2267ED-8E12-4EF7-A639-577470643BFFQ24246084-60479533-49C9-4802-8A23-D47769EE84C6Q24547558-E04E0191-5767-4282-9FD9-B7116D597ABCQ24656644-DE81D337-189B-40AC-98A6-028B399594F1Q24657676-4E740CCE-F798-43D7-A154-4D3790A43AE3Q24669736-7EE2D5C4-CA81-4A6C-89CB-903B90640F18Q24797434-BB9390F3-24AD-491D-878C-7F1CA1105BD7Q25255544-75BB2813-F2C4-4FCF-B2AC-C7910D66F24FQ26778763-7A6272FE-D3E6-49EE-9602-BCD065457A45Q26783350-8EBC5221-4A62-460C-871B-54B25362FCADQ26785454-AD01532A-5CEB-40AD-A0E4-D0AD8FBF4EE6Q26830274-11392029-856C-49E8-AA14-66296824415CQ27001931-6DE973E5-3718-4B05-9456-1ECFDCE2F656Q27016644-EFBDCB50-4FDB-4CC6-A244-B3FA48860682Q27694430-5D1DC1A6-C2C3-4832-BEEC-46656131EC5CQ28069065-2A66A5DB-D203-4299-81CE-87A1399BDE8EQ28075335-AF253357-F59E-48AB-ACED-B9E8081274F9Q28195948-3DBA38D1-CD67-4025-BACB-C9E1333040B2Q28276621-4D9535F0-CA40-4E98-88FB-00761D0DB8B9Q28534790-367A5F85-215A-4F2C-8F3A-A81E5550B558Q28545766-DA69508F-750F-4D08-ABBD-C212E32403ABQ28554592-3056F6CF-A6D6-4A44-BA1B-C214FD85B52EQ28568760-B60420D5-854F-4054-931E-6FB3AECAD7C3Q30410401-38DD70C3-D020-43FC-A0C0-122940CC29E7Q30417363-E202F1B6-D70D-4427-B44E-1EC87AE6A38CQ30426407-A2F2C99C-D3CC-4366-8C33-C953473F9BE3Q30481274-C1DD1149-16FA-4661-8965-9E7914CE205AQ30494654-E73495F5-3EA5-4417-BC4D-7511BA265D61Q31144148-701A7F4A-288F-493B-A608-3A8307C0C4CFQ31895027-18ABE31C-E9B7-44A6-BD20-BC3EACD9C82CQ33453482-76FEFBD3-9156-44B2-9BB8-162A79B8F90BQ33464541-9F6F3B09-A79A-477C-940B-BBF0B85D2E5DQ33558371-E6AEF005-39B9-4543-83EE-35594712BFE8Q33573171-36C18FEE-F11C-4E9C-B6C7-6CC31742C492
P2860
Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.
description
1999 nî lūn-bûn
@nan
1999 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի հունիսին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Glycemic control with diet, su ...... Diabetes Study (UKPDS) Group.
@ast
Glycemic control with diet, su ...... Diabetes Study (UKPDS) Group.
@en
type
label
Glycemic control with diet, su ...... Diabetes Study (UKPDS) Group.
@ast
Glycemic control with diet, su ...... Diabetes Study (UKPDS) Group.
@en
prefLabel
Glycemic control with diet, su ...... Diabetes Study (UKPDS) Group.
@ast
Glycemic control with diet, su ...... Diabetes Study (UKPDS) Group.
@en
P2093
P921
P356
P1476
Glycemic control with diet, su ...... e Diabetes Study (UKPDS) Group
@en
P2093
P304
P356
10.1001/JAMA.281.21.2005
P407
P50
P577
1999-06-01T00:00:00Z